Adjunct Associate Professor Daniel Huang is a Senior Consultant in the Division of Gastroenterology and Hepatology. He previously served as Chief Resident in Internal Medicine at the National University Hospital (NUH) and in the Singapore Chief Residency Programme. He currently leads hepatocellular carcinoma (HCC) research within the Division and is experienced in both diagnostic and therapeutic endoscopy.
Dr Huang’s research focuses on hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis (MASH), and viral hepatitis. He completed an NMRC Research Training Fellowship at the MASLD Research Centre, University of California, San Diego, where he worked on non-invasive strategies to risk-stratify MASH and HCC using advanced imaging, genomic, and RNA-based approaches.
Dr Huang has published several influential studies on the indeterminate phase of chronic hepatitis B, contributing to the expansion of treatment indications in the 2024 World Health Organization hepatitis B guidelines. Dr. Huang also developed the MASH Resolution Index, a non-invasive biomarker for MASH resolution that is now used as an endpoint in phase II clinical trials. He has co-authored clinical practice guidelines for the American Gastroenterological Association (AGA) and is contributing to multiple guidance statements by the Asia-Pacific Association for the Study of the Liver (APASL).
Dr Huang has authored more than 230 peer-reviewed publications, including first- and corresponding-author papers in leading journals such as Hepatology, Journal of Hepatology, Gut, Nature Reviews Disease Primers, and The Lancet Oncology. His work has been supported by several grants from the National Medical Research Council, and he is the principal investigator of multiple translational and clinical studies in MASH and HCC. He leads an international collaborative research network in hepatocellular carcinoma and serves as an Associate Editor of Alimentary Pharmacology & Therapeutics. Dr. Huang also serves on the Executive Committee of the Gastroenterological Society of Singapore (GESS) and as Co-Chair of an Asia-Pacific Gastroenterology Association (APAGE) task force focused on developing the next generation of academic leaders.
1. Huang D.Q., Tran A, Yeh ML, et al. Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
2. Tan EY et al., and Huang DQ. Liver cancer in 2021: Global burden of disease study. J Hepatol. 2024 Oct 30:S0168-8278(24)02652-7.
3. Huang, D. Q., Wilson, A.W, Behling, C. et al. Fibrosis Progression Rate in Biopsy-proven Nonalcoholic Fatty Liver Disease among People with Diabetes versus People without Diabetes: A Multicenter Study. Gastroenterology (2023).
4. Loomba R, …. and Huang DQ. MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH. Gut. 2024 Jul 11;73(8):1343-1349. doi: 10.1136/gutjnl-2023-331401.
5. Huang, D. Q., Fowler, K. J., Liau, J., et al. (2022). Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 55(7), 820-827. doi:10.1111/apt.16844
6. Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 6;11(1):14.
7. Huang D.Q., Nourredin N, Ajmera V, et al. Type 2 Diabetes Mellitus, Hepatic Decompensation and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: Individual Participant Data Meta-analysis. The Lancet Gastroenterology and Hepatology 2023.
8. Huang DQ, Li X, Le MH et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1803-1812.e5
9. Zheng M, Huang D.Q., Konkwo C, et al. Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study. JHEP Rep. 2023 Feb 2;5(4):100692.
10. Huang, D. Q., Muthiah, M. D., Zhou, L et al. (2021). Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 11(5), 1313-1325. doi:10.1016/j.jcmgh.2020.12.009
